Office Based Vergence/Accommodative Therapy for the Treatment of Intermittent Exotropia
NCT ID: NCT04744779
Last Updated: 2021-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2021-03-31
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of Vision Therapy for Intermittent Exotropia
NCT04487249
Exercise Training on a Mirror for Intermittent Exotropia Control Post Strabismus Surgery
NCT06762067
Improving Control of Intermittent Exotropia
NCT07272005
Observation Versus Occlusion Therapy for Intermittent Exotropia
NCT01032330
The Effect of Oculo-Motor Exercises in Intermittent Exotropia
NCT03661476
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
i) To evaluate the short-term effectiveness of office based vergence/accommodative therapy (OBVAT) for improving control of intermittent exotropia compared to observation alone; ii) To evaluate the long-term effectiveness of OBVAT for improving control of intermittent exotropia compared to observation alone; iii) To determine the natural history of intermittent exotropia among patients aged 6 to \< 18 years who have baseline near stereoacuity of 400 arc sec or better using the Preschool Randot stereotest
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observation
Observation only.
No interventions assigned to this group
Office-based accommodative/vergence therapy and home reinforcement
Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
Office-based accommodative/vergence therapy and home reinforcement
Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Office-based accommodative/vergence therapy and home reinforcement
Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 16 weeks) and home reinforcement (15 minutes each time, five times per week, 16 weeks)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Distance exodeviation between 10 and 30 prism diopters (PD) measured by prism and alternate cover test (PACT)
3. Near deviation not exceeding the distance deviation by \>10PD by PACT (i.e., convergence insufficiency type intermittent exotropia excluded)
4. Control of deviation meeting all the following criteria based on the office control score scale:
4.1 Intermittent or constant exotropia at distance (mean of 3 baseline assessments of distance control ≥ Grade 2)# 4.2 Intermittent exotropia or exophoria at near (at least 1 of 3 assessments of near control at the baseline visit Grade 0-4) or orthophoria
5. Stereoacuity: near stereoacuity of 400 arcsec or better by the Preschool Randot stereotest
6. Cycloplegic subjective refraction spherical equivalent (SE) refractive error between -6.00 diopters (D)and +3.50 D inclusive in either eye
7. Must be wearing the updated refractive correction (spectacles) for at least 2 weeks if refractive error (based on cycloplegic subjective refraction performed within 6 months) meets any of the following:
7.1 Myopia \>-0.50 D spherical equivalent in either eye 7.2 Anisometropia \>1.00 D spherical equivalent 7.3 Astigmatism in either eye \>1.50 D
8. Refractive correction must meet the following guidelines:
8.1 Anisometropia spherical equivalent must be within 0.25 D of the full anisometropic difference 8.2 Astigmatism cylinder must be within 0.25 D of full correction and axis must be within 5 degree 8.3 For hyperopia and myopia, the spherical component can be reduced by investigator discretion provided reduction is symmetrical and results in residual (i.e., uncorrected) spherical equivalent refractive error that does not exceed +3.50 D spherical equivalent hyperopia or -0.50 D spherical equivalent myopia
9. Gestational age \>34 weeks
10. Birth weight \>1500 g
11. No previous surgical or nonsurgical treatment for intermittent exotropia other than single vision refractive correction (e.g. progressive addition lens, bifocals, patching, or deliberate over-minus with spectacles \>0.50 D)
12. No prior office-based vision therapy for any reason
13. No prior strabismus surgery or botulinum injection, intraocular surgery, or refractive surgery
14. No planned strabismus surgery
15. Visual acuity correctable to at least 20/25 or better at distance and near in each eye.
Exclusion Criteria
2. Regular use of any ocular or systemic medications known to affect accommodation or vergence system, such as atropine, pirenzepine, and anti-epileptic medications, in the most recent 3 months
3. Developmental disability, attention-deficit/hyperactivity disorder (ADHD), or learning disability diagnosis in children that in the investigator's discretion would interfere with office-based treatment
4. Relocation anticipated within 2 year
5. Significant ocular or neurologic disorders (e.g. cerebral palsy) other than strabismus
6. Vertical deviation greater than 3 pd
7. Household member already in the study
6 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Salus University
OTHER
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ying Kang
Associate Professor of Ophthalmology
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XT4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.